However an accompanying comment questions the advantages of gene therapy over deep-brain stimulation, a current method for treating Parkinson’s disease.
Professor Matthew During, Weill Medical College of Cornell University, New York, USA, and colleagues did a safety and tolerability trial on 11 men and one woman, average age 58 years. The patients were divided into groups of four and given low, medium, or high dose, injections of the glutamic acid decarboxylase (GAD) gene, with associated adeno-associated virus (AAV). The injections were given into the subthalamic nucleus of the brain, and all took place at the Weill Medical College of Cornell University/New York Presbyterian Hospital, USA.
All patients survived the surgery and had no side effects related to gene therapy. Substantial improvements in movement were seen within three months of surgery in the side of the body opposite to that of the brain where injections were given, and continued until 12 months after surgery – the endpoint of the trial. Improvements in motor scores were also seen in both the “on” state (when subjects were on standard medication, and typically not improved with other surgical approaches), as well as the “off” state despite the gene therapy being given in only one hemisphere.
Brain scans also showed reductions in metabolism in the ipsilateral thalamus (IT), similar to reductions which occur after other successful surgery for Parkinson’s disease. The study also showed a correlation between improved clinical motor scores and brain metabolism in the supplementary motor area, again similar to findings reported after surgery of patients with Parkinson’s disease.
The authors also point out that the gene therapy approach has advantages over the currently used deep-brain stimulation method. They say: “The absence of indwelling hardware [for gene therapy] reduces the risk of infection, and some patients with Parkinson’s disease simply prefer not to have the implanted device.” They add that frequent hospital visits would not be necessary for the gene therapy approach.
The authors conclude: “Our results show that AAV-mediated gene transfer can be done safely in the human brain, with no evidence of substantial toxic effects or adverse events in the perioperative period and for at least one year after treatment.”
In the accompanying Comment, Dr Jon Stoessl, Pacific Parkinson’s Research Centre, University of British Columbia, Canada, asks: “Apart from the avoidance of stimulator adjustments and potential hardware problems, what is the real advantage of this approach compared with deep-brain stimulation of the subthalmic nucleus?”
He concludes: “During and colleagues have taken a proactive approach to the treatment of neurodegenerative disease, and should be congratulated for their circumspection in the description of the potential implications of their findings. They made an important step in showing proof of principle, but much work should be done before neurologists and neuroscientists will regard this therapy as an effective approach.”
Tony Kirby | alfa
Navigational view of the brain thanks to powerful X-rays
18.10.2017 | Georgia Institute of Technology
Separating methane and CO2 will become more efficient
18.10.2017 | KU Leuven
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
18.10.2017 | Materials Sciences
18.10.2017 | Physics and Astronomy
18.10.2017 | Physics and Astronomy